uniQure N.V. (NASDAQ:QURE) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $58.9167.

A number of analysts recently weighed in on QURE shares. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. The Goldman Sachs Group increased their price objective on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Chardan Capital raised their target price on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Leerink Partners raised their target price on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday.

uniQure Stock Down 4.1%

QURE stock opened at $44.39 on Thursday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The firm’s 50-day simple moving average is $25.30 and its 200 day simple moving average is $22.30. The stock has a market cap of $2.80 billion, a PE ratio of -12.76 and a beta of 0.98.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, sell-side analysts predict that uniQure will post -3.64 EPS for the current year.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported initial AMT-260 data in temporal lobe epilepsy showing meaningful seizure reductions in early patients, with no treatment-related serious adverse events, which supports the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Early trial updates also highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor optimism around AMT-260’s potential. Article Title
• Neutral Sentiment: The company also announced preliminary data from the first cohort in its Phase I/IIa AMT-260 clinical trial, a routine but important catalyst for a development-stage biotech. Article Title
• Negative Sentiment: uniQure announced a $150 million underwritten public offering, with an additional $22.5 million greenshoe option, which could dilute existing shareholders even if it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may also weigh on sentiment, even though the transactions were made under pre-arranged 10b5-1 plans. Article Title

Insider Activity

In other uniQure news, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. This trade represents a 20.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the transaction, the director directly owned 43,254 shares in the company, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 324,134 shares of company stock worth $12,778,769 in the last 90 days. 4.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Large investors have recently bought and sold shares of the stock. Torren Management LLC acquired a new position in uniQure during the 4th quarter valued at about $28,000. Jones Financial Companies Lllp grew its stake in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure in the 4th quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter worth approximately $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.